SI2252300T1 - Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze - Google Patents

Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze

Info

Publication number
SI2252300T1
SI2252300T1 SI200931588A SI200931588A SI2252300T1 SI 2252300 T1 SI2252300 T1 SI 2252300T1 SI 200931588 A SI200931588 A SI 200931588A SI 200931588 A SI200931588 A SI 200931588A SI 2252300 T1 SI2252300 T1 SI 2252300T1
Authority
SI
Slovenia
Prior art keywords
pyrimidinediamines
atherosclerosis
treatment
Prior art date
Application number
SI200931588A
Other languages
English (en)
Inventor
Esteban Masuda
Jochen Schmitz
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of SI2252300T1 publication Critical patent/SI2252300T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200931588A 2008-02-22 2009-02-20 Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze SI2252300T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22
EP09711944.0A EP2252300B1 (en) 2008-02-22 2009-02-20 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
PCT/US2009/034718 WO2009105675A1 (en) 2008-02-22 2009-02-20 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
SI2252300T1 true SI2252300T1 (sl) 2017-04-26

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931588A SI2252300T1 (sl) 2008-02-22 2009-02-20 Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze

Country Status (21)

Country Link
US (1) US8530466B2 (sl)
EP (1) EP2252300B1 (sl)
JP (1) JP5586482B2 (sl)
KR (1) KR101614555B1 (sl)
CN (1) CN102014917A (sl)
AU (1) AU2009215430B2 (sl)
BR (1) BRPI0907724B8 (sl)
CA (1) CA2715962C (sl)
CY (1) CY1118655T1 (sl)
DK (1) DK2252300T3 (sl)
ES (1) ES2610880T3 (sl)
HK (1) HK1150555A1 (sl)
HR (1) HRP20170050T1 (sl)
HU (1) HUE030307T2 (sl)
LT (1) LT2252300T (sl)
MX (1) MX2010009159A (sl)
PL (1) PL2252300T3 (sl)
PT (1) PT2252300T (sl)
RU (1) RU2490015C2 (sl)
SI (1) SI2252300T1 (sl)
WO (1) WO2009105675A1 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ES2711249T3 (es) 2008-06-27 2019-04-30 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
ES2710423T3 (es) 2011-07-28 2019-04-25 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR20150119012A (ko) 2013-02-08 2015-10-23 셀진 아빌로믹스 리서치, 인코포레이티드 Erk 억제제 및 이의 용도
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2957700C (en) 2014-08-08 2022-12-13 Raffaele Migliaccio Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies.
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69429078T2 (de) * 1993-10-01 2002-07-11 Novartis Ag Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
JP2005526765A (ja) * 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
ATE451381T1 (de) * 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
PT1951684T (pt) 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
CA2655315A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CA2693594A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors

Also Published As

Publication number Publication date
CN102014917A (zh) 2011-04-13
EP2252300B1 (en) 2016-10-19
BRPI0907724B1 (pt) 2019-12-17
CY1118655T1 (el) 2017-07-12
KR101614555B1 (ko) 2016-04-21
BRPI0907724A2 (pt) 2017-06-13
HK1150555A1 (zh) 2012-01-06
HUE030307T2 (en) 2017-04-28
US20110046126A1 (en) 2011-02-24
RU2490015C2 (ru) 2013-08-20
PT2252300T (pt) 2017-01-06
BRPI0907724B8 (pt) 2021-05-25
CA2715962C (en) 2017-03-07
HRP20170050T1 (hr) 2017-03-10
CA2715962A1 (en) 2009-08-27
US8530466B2 (en) 2013-09-10
KR20100126422A (ko) 2010-12-01
AU2009215430B2 (en) 2015-02-12
JP2011513230A (ja) 2011-04-28
WO2009105675A1 (en) 2009-08-27
DK2252300T3 (en) 2017-02-06
EP2252300A1 (en) 2010-11-24
RU2010138899A (ru) 2012-03-27
JP5586482B2 (ja) 2014-09-10
ES2610880T3 (es) 2017-05-03
AU2009215430A1 (en) 2009-08-27
PL2252300T3 (pl) 2017-04-28
LT2252300T (lt) 2017-02-10
MX2010009159A (es) 2010-09-14

Similar Documents

Publication Publication Date Title
HK1150555A1 (zh) 用於治療動脈硬化的 -嘧啶二元胺的應用
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2101785A4 (en) TREATMENT OF IT SEC
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL200796A0 (en) Device for the treatment of laundry using biocides
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
GB0711342D0 (en) Well treatment
GB0800145D0 (en) Skincare treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
ZA201007362B (en) Conjugates for the treatment of mesothelioma
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
HK1145634A1 (en) Treatment of atherosclerosis
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
GB0716784D0 (en) Well treatment
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
GB0602857D0 (en) The treatment of sialorrhoea
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
GB0703492D0 (en) The treatment of hyperhidrosis
GB0703491D0 (en) The treatment of hyperhidrosis
GB0809319D0 (en) The treatment of puritus
GB0821381D0 (en) Compositions for the treatment of dry eye
GB0602855D0 (en) The Treatment Of Sialorrhoea